Dr. Peter Stock is a transplant surgeon who specializes in kidney, liver and pancreas transplants. He is co-director of the Pancreatic Islet Cell Transplantation Program.

In his research, Stock studies body mechanisms that lead to transplant rejection when the donor and recipient are not genetically identical. He also studies chimerism (a therapy to prevent transplant rejection that uses the donor's bone marrow cells) and pancreatic islet cell transplantation (a procedure that can allow people with type 1 diabetes to discontinue insulin therapy).

Stock received his medical training at the University of Minnesota, completing a surgical residency before coming to UCSF for a transplant fellowship. He joined the UCSF faculty in 1992.

Stock is an active teacher and supervises surgical residents and fellows. He is a member of numerous professional and honorary societies.

  • Education

    University of Illinois School of Medicine, 1982

  • Residencies

    University of Minnesota Medical Center, General Surgery, 1990

  • Fellowships

    UCSF Medical Center, Transplant Surgery, 1992

  • Board Certifications

    Surgery, American Board of Surgery

  • Academic Title

    Professor

Clinics I work with

Kidney Transplant Center

400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143

Liver Transplant Program

400 Parnassus Ave., Third Floor
San Francisco, CA 94143

Pancreas Transplant Services

400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143

My reviews

5.0

Overall Experience
38 Reviews
Explained things in a way that was easy to understand
37 Reviews
Did the doctor pay attention to your concerns
38 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
37 Reviews
Knew the important information about your medical history
37 Reviews
The provider showed respect for what you had to say
38 Reviews
The provider spent enough time with me
38 Reviews

Selected research

Decorative Caduceus

Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes

Safety: Since this study is a pilot non-randomized safety and efficacy trial with patient enrollment limited by budgetary constraints, no direct statistical significance tests can be performed.

Recruiting

Decorative Caduceus

HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for...

Time to first of any of the following events: death or graft failure or serious adverse event (SAE) or HIV breakthrough or opportunistic infection

Recruiting

Share